Percheron Therapeutics Limited (FRA:AWY0)

Germany · Delayed Price · Currency is EUR

0.0005

0.00 (0.00%)

Last updated: Oct 23, 2026, 8:04 AM CEST

Market Cap	4.98M -9.0%
Revenue (ttm)	510.83K -53.2%
Net Income	-2.90M
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	356,229
Open	0.0005
Previous Close	0.0005
Day's Range	0.0005 - 0.0005
52-Week Range	0.0005 - 0.0045
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 26, 2026

About Percheron Therapeutics

Percheron Therapeutics Limited engages in the research and development of antisense pharmaceuticals for cancer and rare diseases in Australia. Its products pipeline includes HMBD-002, a recombinant humanised monoclonal IgG4 antibody, which completed phase I clinical trial to treat to human v-domain immunoglobulin suppressor of T-cell activation (VISTA). The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 ... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2000

Employees 8

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol AWY0

Financial Performance

In fiscal year 2026, Percheron Therapeutics's revenue was 843,600, a decrease of -53.16% compared to the previous year's 1.80 million. Losses were -4.79 million, -67.89% less than in 2025.

Financial numbers in AUD Financial Statements